Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

Editor's Note

VOLUME 36, NO. 3 • SEPTEMBER 2019

Tzung-Jeng Hwang, IPA Bulletin Editor-in-Chief

‚ÄčIPA has been very active in the season from June to August. In July, the IPA joined the Alzheimer Association International Conference (AAIC) in Los Angeles to interact and attract colleagues around the world sharing similar interest. In August, some board members (Drs. Brodaty, Ikeda and Hwang) were invited to the ADI Regional meeting to share their experiences in Kuala Lumpur. Finally, our important IPA congress was formally held in Santiago de Compostela where about 450 members from about 40 countries join the meeting. The meeting was a success and there is a short report on the meeting in this issue. Also included is the inaugural address of the Congress Chair, Professor Raimundo Mateos.

In this issue, there are six articles, three in “Research and Practice,” two in “Around the World,” and one in “Technology Corner.

In “Research and Practice”:

Dr. Voineskos (Canada) discuss the link between depression and dementia in late life, and their shared molecular mechanisms. He also introduces a longitudinal study (known as ‘OPTIMUM-NEURO’) designed to clarify the neurobiology of this depression-dementia link. Dr. Appelhof (Netherlands) summarizes her work on the management of neuropsychiatric symptoms in people with young-onset dementia (YOD) and provides valuable suggestions to further improve specialized care for people with YOD. Dr. Borsje (Netherlands) reports neuropsychiatric symptoms are very common in people with dementia in general practices, and almost 30% of patients use psychotropic drugs. Informal caregivers of these people with dementia have a high risk for depression and are likely to have mental problems.

In “Around the World”: 

Dr. Valzolgher (Italy) updates us on the new WHO dementia guideline which represents a part of the WHO’s Global action plan to dementia. The updated guidelines for the prevention of dementia are implemented with practical recommendations for the caregivers, which include healthy lifestyle interventions that promote a reduction in the risk for dementia associated with the benefits of a healthy diet and exercise. Dr. Clarissa Giebel (UK) reflects on the same WHO guideline and points out how difficult some of these implementations might be difficult for people living in low- and middle-income countries. These potential implementation issues are particularly relevant for clinical recommendations, such as the effective management of hypertension and diabetes. 

In “Technology Corner”, following previous articles in this technology corner covering the basics of virtual reality (VR), augmented reality (AR), and mixed reality (MR) technologies, Dr. Shih (Taiwan) et al. dig deeper into the actual and potential applications of augmented reality technology, specifically for persons with dementia. They conclude that AR technology may be regarded as a mediator to facilitate interventions or an enhancer to increase the wellbeing of persons with dementia.

 I cordially invite IPA members to submit articles to share thoughts and experiences with us! Please reach us at IPABulletin@ipa-online.org.

Acknowledgements

Acadia Pharmaceuticals Otsuka Pharmaceuticals Cambridge University Press Avanir Pharmaceuticals
CORPORATE COUNCILS